Denver, Colorado -A powerful convergence of global energy disruption and emerging technology catalysts is reshaping pockets of the market, with select small-cap names ready to make moves.
Shares of Sky Quarry (NASDAQ:SKYQ) have drawn heightened attention as Brent crude surges past $110 per barrel, underscoring a tightening global supply picture. With the Strait of Hormuz facing disruptions and West Coast refining capacity shrinking, Sky Quarry’s position as the operator of Nevada’s only refinery takes on outsized strategic importance. In a region heavily dependent on imported fuel, primarily from California,the closure of major refining assets is amplifying the value of localized production and processing.
This backdrop is fueling speculative momentum across low-float energy-linked equities, including sympathy movement alongside TMD Energy (NYSE:TMDE), as traders look to capitalize on tightening supply-demand dynamics. The broader implication is clear: infrastructure scarcity is becoming just as critical as resource availability, particularly in geographically constrained markets like the U.S. West.
But today’s energy story extends beyond hydrocarbons. It’s increasingly about materials, efficiency, and the systems that support next-generation infrastructure.
That theme is evident in Xeriant Inc. (OTCQB:XERI), which is advancing a breakthrough multilayer fire-resistant composite at a time when energy resilience and climate-related risks are reshaping construction standards. The company’s recent U.S. patent allowance positions its NEXBOARD™ solution at the intersection of safety, sustainability, and performance, key factors as wildfires, extreme weather, and energy infrastructure demands converge. With certification testing underway, Xeriant is moving closer to commercialization in sectors that increasingly demand fire-resistant, lightweight materials.
Meanwhile, Kraig Biocraft Laboratories (OTCQB:KBLB) is pushing the boundaries of bioengineered materials with its recombinant spider silk platform. While not an energy company in the traditional sense, its work speaks directly to efficiency, creating ultra-strong, lightweight fibers that could ultimately reduce material loads and energy consumption across industries ranging from apparel to aerospace. As production scales toward industrial output, Kraig’s progress highlights how biological manufacturing could play a role in future resource optimization.
Of course, biotech continues to advance new solutions and, on the data side of the equation, Totaligent (OTCID:TGNT) is quietly aligning itself with another critical layer of the energy transition: information. As AI infrastructure expands and healthcare converges with advanced analytics, the ability to structure and activate large-scale datasets is becoming foundational. Totaligent’s pivot toward biologics-driven data capabilities reflects a broader shift in which data infrastructure may become as essential as physical infrastructure in enabling next-generation energy, healthcare, and industrial systems.
Biodexa Pharmaceuticals (NASDAQ:BDRX) is emerging as a notable trade today after announcing a strategic manufacturing partnership with Syngene International to produce GMP clinical trial supplies for its lead oncology candidate MTX240, a novel molecular glue therapy targeting treatment-resistant gastrointestinal stromal tumors (GIST). The collaboration signals accelerating momentum toward the clinic, with Biodexa moving rapidly from its recent licensing agreement to scalable production in just weeks, highlighting operational execution and urgency. MTX240’s differentiated mechanism, designed to bypass resistance pathways that limit traditional kinase inhibitors, positions it as a potentially meaningful entrant in a high-unmet-need oncology segment. With plans to file an IND and initiate a Phase 1b/2a study later this year, the Syngene partnership not only de-risks near-term manufacturing but also reinforces investor focus on upcoming clinical catalysts, placing BDRX firmly on the radar as a momentum-driven biotech name.
Cocrystal Pharma (NASDAQ:COCP) is gaining attention after receiving FDA Fast Track designation for its oral antiviral candidate CDI-988, aimed at both the treatment and prevention of norovirus infection—a widespread illness responsible for an estimated 685 million cases globally each year. The designation is designed to accelerate development and regulatory review for therapies addressing serious unmet medical needs, enabling more frequent FDA interaction, potential rolling NDA submission, and eligibility for Priority Review. CDI-988 targets a highly conserved viral protease shared across noroviruses and other pathogens, offering a differentiated, structure-based approach to antiviral development. With a Phase 1b challenge study currently underway at Emory University School of Medicine, the program represents a potentially important step toward addressing a major gap in infectious disease treatment, particularly for vulnerable populations where norovirus can lead to prolonged and severe illness.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact [email protected] to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
Sources include:
https://ir.cocrystalpharma.com/press-releases/detail/226
National Geographic March 2026 Cover Feature (February 23, 2026)
https://www.kraiglabs.com/kraig-biocraft-laboratories-advancements-in-spider-silk-featured-as-the-cover-of-national-geographics-march-2026-issue/ and https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering
PAID EDITORIAL DISCLOSURE: This editorial communication intended for informational purposes only. 247 is a third-party media provider and the editor of this article holds a personal investment position in XERI. This ownership may be considered a potential conflict of interest. Readers are encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The editor may be compensated for providing future XERI market outreach and other services, for providing ongoing TGNT market outreach and other services, 24/7 owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://go.247marketnews.com/tgnt-disclosure/ or https://go.247marketnews.com/kblb-disclosure/ for further disclosure information.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.